HighMark Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

HighMark Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-209	Closed	-$19K	–	522
2021 Q3	$19K	Buy	209 +113	+118%	+$10.2K	0.01%	186
2021 Q2	$9K	Buy	96 +13	+16%	+$1.35K	0.01%	275
2021 Q1	$9K	Sell	83 -39	-32%	-$5.31K	0.01%	250
2020 Q4	$17K	Sell	122 -601	-83%	-$71.3K	0.01%	176
2020 Q3	$59K	Buy	723 +622	+616%	+$51.6K	0.05%	95
2020 Q2	$8K	Buy	+101	New	+$6.68K	0.01%	244

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighMark Wealth Management's RARE Position: Q4 2021 in Review

HighMark Wealth Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 209 shares — an estimated $19K sold.

HighMark Wealth Management first reported a position in RARE in Q2 2020 and held it in 6 quarters. The position peaked at $59K in Q3 2020. 234 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

HighMark Wealth Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
HighMark Wealth Management sold 209 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $19K.
HighMark Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and held it in 6 quarters.
HighMark Wealth Management's Ultragenyx Pharmaceutical position peaked at $59K in Q3 2020.
234 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on HighMark Wealth Management's 13F filing for Q4 2021, filed 20 Jan 2022.